Erythromelalgia mimicking diabetic foot infection: diagnostic challenges and contraindication of ice application
Abstract
Background: Erythromelalgia (EM) is a neurovascular disorder with an estimated incidence of 0.25-2 cases per 100,000 people, characterized by episodic burning pain, erythema, and increased skin temperature, primarily in the extremities. Its presentation can be mistaken for diabetic foot infection (DFI), leading to diagnostic dilemmas and potentially harmful therapeutic interventions.
Case presentation: A 62-year-old Han Chinese woman with diabetes presented with recurrent redness, swelling, burning pain, and ulceration on both feet. She was once misdiagnosed as DFI, but was finally confirmed as EM based on characteristic symptoms (heat intolerance, relief with cautious cooling) in the absence of infectious signs (fever, leukocytosis, or purulence). During the treatment, the patient was significantly alleviated. However, she suffered from gangrene and went through amputation due to use of ice packs.
Conclusion: This case not only demonstrates the critical importance of differentiating EM from DFI, but also emphasizes the necessity of avoiding ice therapy in its management, providing valuable insights for clinical practice.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 100,000 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.